CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Auspex Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Auspex Pharmaceuticals Inc
3333 N Torrey Pines Ct Ste 400
Phone: (858) 558-2400p:858 558-2400 LA JOLLA, CA  92037-1023  United States Ticker: ASPXASPX
This company was Merged or Acquired on 5/5/2015.
This company ceased filing statements with the SEC on 5/15/2015.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Auspex Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for the treatment of orphan diseases. The Company’s pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, an orphan disease, and tardive dyskinesia and Tourette syndrome, subsets of either of which may be deemed to be orphan diseases, as well as other orphan indications. Its product candidate, SD-809, is in a Phase 3 registration clinical trial for the treatment of chorea associated with Huntington’s disease. Using its know-how in deuterium chemistry, it made chemical modifications at specific positions in the tetrabenazine molecule to create the drug candidate SD-809 (dutetrabenazine). Deuterium is a non-toxic, naturally occurring form of hydrogen.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201412/31/2014YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director PratikShah 45 10/22/2013 6/1/2007
Chief Financial Officer John P.Schmid 52 9/1/2013 9/1/2013
Chief Operating Officer Bharatt M.Chowrira 50 10/1/2013 10/1/2013
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 35 (As of 12/31/2014)
Outstanding Shares: 31,815,187 (As of 2/27/2015)
Shareholders: 20
Stock Exchange: NASD
Federal Tax Id: 954862842
Fax Number: (858) 558-2401


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023